当前位置: 首页 >> 检索结果
961. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
作者: B R Yacyshyn.;M B Bowen-Yacyshyn.;L Jewell.;J A Tami.;C F Bennett.;D L Kisner.;W R Shanahan.
来源: Gastroenterology. 1998年114卷6期1133-42页
Intercellular adhesion molecule 1 (ICAM-1) plays an important role in the trafficking and activation of leukocytes and is up-regulated in inflamed mucosa in Crohn's disease. ISIS 2302 is an antisense phosphorothioate oligodeoxynucleotide that inhibits ICAM-1 expression. The aim of this study was to obtain preliminary assessment of tolerability, pharmacology, and efficacy of ISIS 2302 in Crohn's disease.
962. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.
作者: E M Sokal.;H S Conjeevaram.;E A Roberts.;F Alvarez.;E M Bern.;P Goyens.;P Rosenthal.;A Lachaux.;M Shelton.;J Sarles.;J Hoofnagle.
来源: Gastroenterology. 1998年114卷5期988-95页
Treatment of chronic hepatitis B with interferon alfa is not approved in children. The aim of this study was to evaluate the safety and efficacy of interferon alfa (IFN-alpha) in children with chronic hepatitis B and increased transaminase levels.
963. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
作者: J R Green.;A J Lobo.;C D Holdsworth.;R J Leicester.;J A Gibson.;G D Kerr.;H J Hodgson.;K J Parkins.;M D Taylor.
来源: Gastroenterology. 1998年114卷1期15-22页
Aminosalicylates are widely used in the treatment of ulcerative colitis (UC). Balsalazide is a novel mesalamine prodrug, activated by colonic bacteria. The aim of this study was to compare the efficacy and safety of balsalazide with that of a pH-dependent formulation of mesalamine in active UC.
964. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients.
Guidelines on the type and frequency of follow-up of patients after curative surgery for colorectal cancer are unclear. The aim of this study was to determine the survival benefit of a planned follow-up program.
965. Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease.
作者: R S McLeod.;B G Wolff.;A H Steinhart.;P W Carryer.;K O'Rourke.;D F Andrews.;J E Blair.;J R Cangemi.;Z Cohen.;J B Cullen.;R G Chaytor.;G R Greenberg.;N M Jaffer.;K N Jeejeebhoy.;R L MacCarty.;R L Ready.;L H Weiland.
来源: Gastroenterology. 1997年113卷6期1823-7页
The aim of this study was to determine the risk of endoscopic/radiological recurrence of Crohn's disease postoperatively and the long-term outcome.
967. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.
作者: D T Lau.;J Everhart.;D E Kleiner.;Y Park.;J Vergalla.;P Schmid.;J H Hoofnagle.
来源: Gastroenterology. 1997年113卷5期1660-7页
Therapy with interferon alfa (IFN-alpha) leads to remission of disease in one third of patients with chronic hepatitis B. The aim of this study was to better define the long-term prognosis of this outcome.
968. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C.
作者: L Chemello.;L Cavalletto.;C Donada.;P Bonetti.;P Casarin.;F Urban.;E Bernardinello.;P Pontisso.;A Alberti.
来源: Gastroenterology. 1997年113卷5期1654-9页
Approximately 75%-85% of patients with chronic hepatitis C virus (HCV) infection do not have a sustained response when treated with interferon (IFN). Limited information exists on the efficacy of retreatment with IFN alone in these patients. The aim of this study was to define the efficacy of IFN retreatment in chronic hepatitis C.
969. Endoscopic assessment of variceal volume and wall tension in cirrhotic patients: effects of pharmacological therapy.
作者: A Escorsell.;J M Bordas.;F Feu.;J C García-Pagán.;A Ginès.;J Bosch.;J Rodés.
来源: Gastroenterology. 1997年113卷5期1640-6页
Variceal rupture is believed to occur when variceal wall tension is excessive. The combined use of endosonography, allowing the objective measurement of variceal radius, and endoscopic measurement of transmural variceal pressure may enable assessment of this important parameter. The aim of this study was to assess the effects on variceal hemodynamics of drugs acting through different mechanisms: decreasing portocollateral blood flow (propranolol) or resistance (isosorbide-5-mononitrate [ISMN]).
970. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis.
Isosorbide-5-mononitrate (Is-5-Mn) exerts beneficial hemodynamic effects in portal hypertension, yet the long-term clinical value is uncertain. The aim of this study was to determine the long-term effects of Is-5-Mn vs. propranolol (Pro) on first bleeding, complications, and death in cirrhosis.
971. Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding.
作者: P Sauer.;L Theilmann.;W Stremmel.;C Benz.;G M Richter.;A Stiehl.
来源: Gastroenterology. 1997年113卷5期1623-31页
In patients with cirrhosis of the liver, after the first variceal bleeding episode, transjugular intrahepatic portosystemic stent shunting (TIPS) and endoscopic sclerotherapy plus propranolol (ES) were compared regarding prevention of variceal rebleeding and mortality.
972. Growth hormone therapy in patients with cirrhosis: a pilot study of efficacy and safety.
作者: A Donaghy.;R Ross.;C Wicks.;S C Hughes.;J Holly.;A Gimson.;R Williams.
来源: Gastroenterology. 1997年113卷5期1617-22页
The protein catabolic state of cirrhosis is associated with severe growth hormone (GH) resistance, with low levels of insulin-like growth factor (IGF)-I and its major binding protein (IGFBP)-3. The aim of this study was to conduct a randomized, double-blind, placebo-controlled pilot study of GH therapy in 20 cirrhotic patients to assess the reversibility of GH resistance and subsequent impact on protein economy and safety.
975. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.
作者: F H Wolfhagen.;E Sternieri.;W C Hop.;G Vitale.;M Bertolotti.;H R Van Buuren.
来源: Gastroenterology. 1997年113卷4期1264-9页
The efficacy of currently available therapeutic agents for cholestatic pruritus is often disappointing. The aim of this study was to assess the antipruritic effect of naltrexone, an oral opiate receptor antagonist.
976. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study.
作者: F Nevens.;J Main.;P Honkoop.;D L Tyrrell.;J Barber.;M T Sullivan.;J Fevery.;R A De Man.;H C Thomas.
来源: Gastroenterology. 1997年113卷4期1258-63页
Lamivudine inhibits hepatitis B virus replication. This study investigated 6 months of lamivudine treatment at three doses.
977. Fructose transport mechanisms in humans.
作者: X Shi.;H P Schedl.;R M Summers.;G P Lambert.;R T Chang.;T Xia.;C V Gisolfi.
来源: Gastroenterology. 1997年113卷4期1171-9页
The possible mechanisms of fructose transport are diffusion, a disaccharidase-related transport system, and glucose-facilitated fructose transport. However, these mechanisms in the human small intestine have not been systematically examined. This study was designed to investigate the mechanisms of fructose transport in the human duodenojejunum.
978. Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study.
作者: J S Scolapio.;M Camilleri.;C R Fleming.;L V Oenning.;D D Burton.;T J Sebo.;K P Batts.;D G Kelly.
来源: Gastroenterology. 1997年113卷4期1074-81页
The effects of parenteral growth hormone, glutamine supplementation, and a high carbohydrate-low fat (HCLF) diet on gut adaptation in short-bowel syndrome are unclear. The aim of this study was to compare effects of this treatment regimen and placebo in patients with short-bowel syndrome.
|